Under the terms of the agreement, STADA has acquired the existing distribution and Nizoral Cream business in Vietnam, the Philippines, and Thailand, as well as the trademark rights in Hong Kong, Australia, Indonesia, Malaysia, New Zealand, and Singapore.
The transaction in an extension of a previous asset deal in Asia-Pacific. In 2018, STADA acquired the Nizoral brand in key European, Middle Eastern, and African (EMEA) markets.
“We are delighted to take this important step of expansion in Asia-Pacific. This partnership further strengthens STADA´s role as a partner of choice in consumer healthcare,” said STADA executive vice president for emerging markets Stephane Jacqmin.
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialised pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 115 countries.
In the 2023 financial year, STADA achieved group sales of EUR3.74 billion ($4.15 billion) and reported earnings before interest, taxes, depreciation and amortisation of EUR802 million ($890 million). As of December 31, 2023, STADA employed 11,667 people worldwide.
 | Germany's STADA expands presence in Vietnam's healthcare market STADA and its Vietnamese affiliate Pymepharco have announced the establishment of its new head office in Ho Chi Minh City, paving the way for further expansion in Vietnam's healthcare market. |
 | Pharmaceutical players seek expansion of rights in Vietnam While continuing to make positive business results in Vietnam’s pharma market in the first half of 2024, multinationals are seeking an expansion of their rights. |
 | Vietnam welcomes major Indian pharmaceutical investments Leading Indian pharmaceutical corporations proposed significant investments in Vietnam, including a $5 billion eco-industrial park, underscoring Vietnam's attractiveness as a prime destination for foreign pharmaceutical investments. |
Tag:
Mobile Version